March 1, 2024 — Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat ...
Drug-Eluting Balloons
This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.
-
-
September 6, 2023 — The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 late-breaking clinical trials. TCT is the annual scientific symposium of CRF and the world’s premier ...
-
The European interventional cardiology device market is one of the larger markets in the global space. The market is driven by the regions aging population and the health care systems demands for ...
-
October 18, 2022 — Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of $35M and ...
April 2, 2024 — Medical device technology developer Concept Medical has announced it has been granted Investigational ...
April 02, 2024
March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug ...
March 20, 2024
March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...
March 13, 2024
March 1, 2024 — Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) ...
March 01, 2024
November 1, 2023 — The VIVA Foundation has announced the results for the first Late-Breaking Clinical Trial sessions at ...
November 01, 2023
October 30, 2023 — Boston Scientific Corporation on Friday announced positive 12-month results from the pivotal AGENT ...
October 30, 2023
September 14, 2023 — BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry ...
September 14, 2023
September 11, 2023 — The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease t ...
September 11, 2023
September 6, 2023 — The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 late-breaking clinical ...
September 06, 2023
August 28, 2023 — Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not ...
August 28, 2023
July 14, 2023 — BIOTRONIK announced the one-year subgroup results from the investigator-initiated BIOPACT randomized ...
July 14, 2023
May 30, 2023 — Twelve-month results from the SELUTION SFA trial have been presented for the first time at the Japan ...
May 30, 2023
May 30, 2023 — The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Conce ...
May 30, 2023
May 12, 2023 — The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc’s novel ...
May 12, 2023
May 4, 2023 — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the Ca ...
May 04, 2023© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now